Pre-made Cixutumumab benchmark antibody ( Whole mAb, anti-IGF1R therapeutic antibody, Anti-IGFR/CD221/IGFIR/JTK13 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Cixutumumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cixutumumab (IMC-A12) is a human monoclonal antibody for the treatment of solid tumors.
| Products Name (INN Index) | Pre-Made Cixutumumab biosimilar, Whole mAb, Anti-IGF1R Antibody: Anti-IGFR/CD221/IGFIR/JTK13 therapeutic antibody |
|---|---|
| INN Name | Cixutumumab |
| Target | IGF1R |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2008 |
| Year Recommended | 2009 |
| Companies | Eli Lilly,ImClone Systems,M. D. Anderson Cancer Center,National Cancer Institute (USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Breast cancer,Colorectal cancer,Head and neck cancer,Liver cancer,Neuroendocrine tumours,Non-small cell lung cancer,Oesophageal cancer,Pancreatic cancer,Prostate cancer,Rhabdomyosarcoma,Sarcoma,Soft |
| Development Tech | Dyax Human Phage Display |
| Previous Name | NA |
| Gm Offical Target Name | IGF1R |
| Package |
